PROCYTE CORP. FILES AMENDMENT TO REGISTRATION STATEMENT WITH S.E.C.
KIRKLAND, Wash., Jan. 7 /PRNewswire/ -- ProCyte Corp. (NASDAQ-NMS: PRCY) announced today that it has filed an amendment to its previously filed S-1 registration statement with the Securities and Exchange Commission containing a prospectus for the proposed new issue of two and one-half million shares of the company's common stock. The offering was announced previously and was briefly postponed. The offering will be co-managed by Wertheim Schroder & Co. Inc. and Dain Bosworth Inc. ProCyte Corp. is a pharmaceutical company engaged in the development of a proprietary class of copper therapeutic compounds for topical and systemic application to human health care needs. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor any offers to buy be accepted prior to the time the registration statement becomes effective. This announcement does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A copy of the written preliminary prospectus may be obtained from Wertheim Schroder & Co., 212-492-6900. -0- 1/7/94 /CONTACT: Karen L. Hedine, vice president, or Joseph Ashley, president and chief executive officer, of ProCyte, 206-820-4548/ (PRCY)
CO: ProCyte Corp.; Wertheim Schroder & Co. Inc.; Dain Bosworth Inc. ST: Washington IN: MTC SU: OFR
JH-IC -- SE002 -- 0033 01/07/94 08:32 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 7, 1994|
|Previous Article:||FLORAFAX INTERNATIONAL REPORTS RESULTS|
|Next Article:||INFOTAINMENT WORLD SIGNS NEW LICENSING AGREEMENT FOR GAMEPRO MAGAZINE WITH EDITORIAL AMERICA, S.A.|